Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Alfred L. Garfall et al.|New England Journal of Medicine|2022Cited by 1.2k
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 studyAjay K. Nooka, Niels W.C.J. van de Donk, Cesar Rodriguez et al.|Cancer|2023Cited by 87
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A. Frerichs, Niels W.C.J. van de Donk, Cesar Rodriguez et al.|Blood Advances|2023Cited by 85
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Cesar Rodriguez, María‐Victoria Mateos et al.|Cancer|2023Cited by 66
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortés‐Selva, Raluca Verona, Tatiana Perova et al.|Blood|2024Cited by 60